2021
Alkaloids of Zephyranthes citrina (Amaryllidaceae) and their implication to Alzheimer's disease: Isolation, structural elucidation and biological activity
KOHELOVA, E., J. MARIKOVA, J. KORABECNY, D. HULCOVA, T. KUCERA et. al.Základní údaje
Originální název
Alkaloids of Zephyranthes citrina (Amaryllidaceae) and their implication to Alzheimer's disease: Isolation, structural elucidation and biological activity
Autoři
KOHELOVA, E., J. MARIKOVA, J. KORABECNY, D. HULCOVA, T. KUCERA, D. JUN, J. CHLEBEK, J. JENCO, M. SAFRATOVA, M. HRABINOVA, A. RITOMSKA, Milan MALANÍK (203 Česká republika, domácí), R. PERINOVA, K. BREITEROVA, J. KUNES, L. NOVAKOVA, L. OPLETAL a L. CAHLIKOVA (garant)
Vydání
Bioorganic Chemistry, SAN DIEGO, ACADEMIC PRESS INC ELSEVIER SCIENCE, 2021, 0045-2068
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.307
Kód RIV
RIV/00216224:14160/21:00122468
Organizační jednotka
Farmaceutická fakulta
UT WoS
000618103400009
Klíčová slova anglicky
Zephyranthes citrina; Amaryllidaceae; Alkaloids; Narcieliine; Alzheimer's disease; Docking studies
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 3. 2022 16:37, JUDr. Sabina Krejčiříková
Anotace
V originále
Twenty known Amaryllidaceae alkaloids of various structural types, and one undescribed alkaloid of narcikachnine-type, named narcieliine (3), have been isolated from fresh bulbs of Zephyranthes citrina. The chemical structures of the isolated alkaloids were elucidated by a combination of MS, HRMS, 1D and 2D NMR, and CD spectroscopic techniques, and by comparison with literature data. The absolute configuration of narcieliine (3) has also been determined. Compounds isolated in a sufficient quantity were evaluated for their in vitro acetylcholinesterase (AChE; E.C. 3.1.1.7), butyrylcholinesterase (BuChE; E.C. 3.1.1.8), and prolyl oligopeptidase (POP; E.C. 3.4.21.26) inhibition activities. Significant human AChE/BuChE (hAChE/hBuChE) inhibitory activity was demonstrated by the newly described alkaloid narcieliine (3), with IC50 values of 18.7 +/- 2.3 mu M and 1.34 +/- 0.31 mu M, respectively. This compound is also predicted to cross the blood-brain barrier (BBB) through passive diffusion. The in vitro data were further supported by in silico studies of 3 in the active site of hAChE/hBuChE.